VCRE logo

VICORE PHARMA HOLDING AB ADR

VCRENASDAQ
🏆 #3365 by market capEarnings Nov 5US Equity
$10.20▲ $0.44 (+4.51%)
Latest quote
🔔
Track VCRE
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.5%
7d▼ 1.8%
14d▲ 12.3%
30d▼ 0.3%
ytd—
1y—
🏦Market Cap
$2.87B
Small Cap
📈Revenue Growth (YoY)
-48.4%
Declining
📊Gross Margin
360.3%
High
💵FCF Margin
—
⚖️P/S Ratio
689.4x
Expensive
Otter Score
36
Weak

Trading Snapshot

Day Range
$9.96 – $10.22
52-Week Range
—
Volume (shares)
9,899
Avg Volume (shares)
—
Shares Outstanding
281.6M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
$4M
Last Q Revenue
$228,246
P/E Ratio
—
P/S Ratio
689.4x
EPS (TTM)
—
Dividend Yield
—
Dilution (1yr)
+18.4%
VCRE logo

VICORE PHARMA HOLDING AB ADR

VCRE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$4M▼ −96.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$454M▲ +138.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$376M▲ +127.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
25.6M▲ +18.4% YoY
StockOtter · stockotter.space

About VICORE PHARMA HOLDING AB ADR

Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The company was founded in 2000 sand is headquartered in Stockholm, Sweden.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
36/100

Analyst Ratings

ⓘ
Consensus
Buy
13 analysts
Strong Buy5
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

Accesswire·16d ago

Vicore Pharma to Participate in the Chardan Healthcare Conference

STOCKHOLM, SE / ACCESS Newswire / October 13, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, today announced t

Accesswire·29d ago

Increase in Number of Shares and Votes in Vicore Pharma

STOCKHOLM, SE / ACCESS Newswire / September 30, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists, today announced

Accesswire·Sep 17

Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation Forum

STOCKHOLM, SE / ACCESS Newswire / September 17, 2026 / Vicore Pharma Holding AB (publ) (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II

Accesswire·Sep 1

Vicore Pharma to Participate in Upcoming Healthcare Conferences

STOCKHOLM, SE / ACCESS Newswire / September 1, 2026 / Vicore Pharma Holding AB (STO:VICO))(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2

Accesswire·Aug 24

Vicore Pharma to Present at the European Respiratory Society Congress 2026

STOCKHOLM, SE / ACCESS Newswire / August 24, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin